<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343629</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000473167</org_study_id>
    <secondary_id>MAYO-03-1-BIO</secondary_id>
    <secondary_id>MAYO-CPN0576</secondary_id>
    <secondary_id>MAYO-05-004233</secondary_id>
    <nct_id>NCT00343629</nct_id>
  </id_info>
  <brief_title>Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers</brief_title>
  <official_title>Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving healthy volunteers sulindac capsules or sulindac tablets may help doctors&#xD;
      learn which form of the drug may be more effective in preventing cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying sulindac capsules to see how well they&#xD;
      work compared with sulindac tablets in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the systemic exposure of sulindac tablets vs sulindac capsules in healthy&#xD;
           volunteers.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the terminal half-life and time of peak drug concentration of sulindac tablets&#xD;
           vs sulindac capsules.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Participants are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Participants receive one sulindac capsule followed 7-10 days later by one&#xD;
           sulindac tablet.&#xD;
&#xD;
        -  Arm II: Participants receive one sulindac tablet followed 7-10 days later by one&#xD;
           sulindac capsule.&#xD;
&#xD;
      Blood is collected periodically during treatment for pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, participants are followed at 7-10 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulindac</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy volunteer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Hemoglobin ≥ 12.0 g/dL (women)&#xD;
&#xD;
          -  Hemoglobin ≥ 13.5 g/dL (men)&#xD;
&#xD;
          -  WBC &gt; 3,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  ALT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  No history of allergic reactions or hypersensitivity to sulindac or other NSAIDs,&#xD;
             including aspirin-sensitive asthma or urticaria&#xD;
&#xD;
          -  No condition that interferes with ingestion or absorption of oral medications&#xD;
&#xD;
          -  No cancer within the past 3 years except nonmelanomatous skin cancer, localized&#xD;
             prostate cancer, carcinoma in situ of the cervix, or superficial bladder cancer that&#xD;
             was previously treated &gt; 6 months ago&#xD;
&#xD;
          -  No uncontrolled concurrent illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Myocardial infarction in the past 6 months&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Chronic liver disease&#xD;
&#xD;
               -  Hypertension that is difficult to control&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit study compliance&#xD;
&#xD;
          -  No other significant clinical disorder or laboratory finding that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No consumption of alcoholic or caffeinated beverages for ≥ 24 hours prior to study&#xD;
             drug administration and until all blood samples have been drawn&#xD;
&#xD;
          -  Willing to provide required biologic specimens&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 6 months since prior investigational agents&#xD;
&#xD;
          -  More than 6 months since prior regular use of (defined as a frequency of 7 consecutive&#xD;
             days for &gt; 3 weeks or &gt; 21 days total) or other concurrent nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2 inhibitors including, but&#xD;
             not limited to, the following:&#xD;
&#xD;
               -  Ibuprofen&#xD;
&#xD;
               -  Ketoprofen&#xD;
&#xD;
               -  Naproxen&#xD;
&#xD;
          -  More than 6 weeks since prior oral corticosteroids&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent use of any of the following:&#xD;
&#xD;
               -  Methotrexate&#xD;
&#xD;
               -  Corticosteroids&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
               -  Ticlopidine&#xD;
&#xD;
               -  Clopidogrel&#xD;
&#xD;
               -  Low molecular weight heparins&#xD;
&#xD;
               -  Abciximab&#xD;
&#xD;
               -  Dipyridamole&#xD;
&#xD;
               -  Eptifibatide&#xD;
&#xD;
               -  Tirofiban&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Hydralazine&#xD;
&#xD;
               -  Angiotensin-converting enzymes (ACE) inhibitors&#xD;
&#xD;
                    -  ACE-receptor antagonists allowed&#xD;
&#xD;
               -  Angiotensin-receptor blockers&#xD;
&#xD;
               -  Ginkgo&#xD;
&#xD;
               -  Ketorolac&#xD;
&#xD;
               -  Levofloxacin&#xD;
&#xD;
               -  Loop diuretics&#xD;
&#xD;
               -  Meadowsweet&#xD;
&#xD;
               -  Selective serotonin reuptake inhibitors&#xD;
&#xD;
               -  Danaparoid&#xD;
&#xD;
          -  No concurrent regular aspirin use unless prescribed by a physician for prevention&#xD;
&#xD;
               -  A maximum of one aspirin (81 mg/day) allowed&#xD;
&#xD;
          -  No concurrent herbal products (e.g., saw palmetto or Hypericum perforatum [St. John's&#xD;
             wort])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J. Limburg, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

